NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

NCT02393924

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Interventions: No intervention

Countries: United Kingdom

This disease registry is a prospective, multicenter non-interventional study designed to observe the different anticancer treatment regimens and their sequencing throughout the course of the disease in participants with unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) and to describe the clinical outcome for each treatment regimen measured as progression-free survival.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Initially diagnosed with HER2-positive unresectable LABC or mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time
* Able and willing to provide written informed consent and to comply with the study protocol

Exclusion Criteria:

\- There are no exclusion criteria for entry into this study

Locations (30)

Canterbury, United Kingdom
Chesterfield, United Kingdom
Cornwall, United Kingdom
Cottingham, United Kingdom
East Kilbride, United Kingdom
Gateshead, United Kingdom
Inverness, United Kingdom
Larbert, United Kingdom
London, United Kingdom
London, United Kingdom
London, United Kingdom
Macclesfield, United Kingdom
Maidstone, United Kingdom
Manchester, United Kingdom
Middlesbrough, United Kingdom
Northampton, United Kingdom
Northwood, United Kingdom
Norwich, United Kingdom
Nottingham, United Kingdom
Plymouth, United Kingdom
Preston, United Kingdom
Rhyl, United Kingdom
Scarborough, United Kingdom
Shrewsbury, United Kingdom
Sutton, United Kingdom
Swansea, United Kingdom
Swindon, United Kingdom
Wakefield, United Kingdom
Yeovil, United Kingdom
York, United Kingdom